296 related articles for article (PubMed ID: 28450074)
1. Structural Basis of MeCP2 Distribution on Non-CpG Methylated and Hydroxymethylated DNA.
Sperlazza MJ; Bilinovich SM; Sinanan LM; Javier FR; Williams DC
J Mol Biol; 2017 May; 429(10):1581-1594. PubMed ID: 28450074
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for the ability of MBD domains to bind methyl-CG and TG sites in DNA.
Liu K; Xu C; Lei M; Yang A; Loppnau P; Hughes TR; Min J
J Biol Chem; 2018 May; 293(19):7344-7354. PubMed ID: 29567833
[TBL] [Abstract][Full Text] [Related]
3. MeCP2 binds to non-CG methylated DNA as neurons mature, influencing transcription and the timing of onset for Rett syndrome.
Chen L; Chen K; Lavery LA; Baker SA; Shaw CA; Li W; Zoghbi HY
Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5509-14. PubMed ID: 25870282
[TBL] [Abstract][Full Text] [Related]
4. Plasticity at the DNA recognition site of the MeCP2 mCG-binding domain.
Lei M; Tempel W; Chen S; Liu K; Min J
Biochim Biophys Acta Gene Regul Mech; 2019 Sep; 1862(9):194409. PubMed ID: 31356990
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation in the gene body influences MeCP2-mediated gene repression.
Kinde B; Wu DY; Greenberg ME; Gabel HW
Proc Natl Acad Sci U S A; 2016 Dec; 113(52):15114-15119. PubMed ID: 27965390
[TBL] [Abstract][Full Text] [Related]
6. P152R Mutation Within MeCP2 Can Cause Loss of DNA-Binding Selectivity.
Franklin D
Interdiscip Sci; 2019 Mar; 11(1):10-20. PubMed ID: 30673959
[TBL] [Abstract][Full Text] [Related]
7. Effects of Rett syndrome mutations of the methyl-CpG binding domain of the transcriptional repressor MeCP2 on selectivity for association with methylated DNA.
Ballestar E; Yusufzai TM; Wolffe AP
Biochemistry; 2000 Jun; 39(24):7100-6. PubMed ID: 10852707
[TBL] [Abstract][Full Text] [Related]
8. Binding Analysis of Methyl-CpG Binding Domain of MeCP2 and Rett Syndrome Mutations.
Yang Y; Kucukkal TG; Li J; Alexov E; Cao W
ACS Chem Biol; 2016 Oct; 11(10):2706-2715. PubMed ID: 27356039
[TBL] [Abstract][Full Text] [Related]
9. DNA binding restricts the intrinsic conformational flexibility of methyl CpG binding protein 2 (MeCP2).
Hansen JC; Wexler BB; Rogers DJ; Hite KC; Panchenko T; Ajith S; Black BE
J Biol Chem; 2011 May; 286(21):18938-48. PubMed ID: 21467044
[TBL] [Abstract][Full Text] [Related]
10. The molecular basis of variable phenotypic severity among common missense mutations causing Rett syndrome.
Brown K; Selfridge J; Lagger S; Connelly J; De Sousa D; Kerr A; Webb S; Guy J; Merusi C; Koerner MV; Bird A
Hum Mol Genet; 2016 Feb; 25(3):558-70. PubMed ID: 26647311
[TBL] [Abstract][Full Text] [Related]
11. Functional analyses of MeCP2 mutations associated with Rett syndrome using transient expression systems.
Kudo S; Nomura Y; Segawa M; Fujita N; Nakao M; Dragich J; Schanen C; Tamura M
Brain Dev; 2001 Dec; 23 Suppl 1():S165-73. PubMed ID: 11738866
[TBL] [Abstract][Full Text] [Related]
12. Tyr120Asp mutation alters domain flexibility and dynamics of MeCP2 DNA binding domain leading to impaired DNA interaction: Atomistic characterization of a Rett syndrome causing mutation.
D'Annessa I; Gandaglia A; Brivio E; Stefanelli G; Frasca A; Landsberger N; Di Marino D
Biochim Biophys Acta Gen Subj; 2018 May; 1862(5):1180-1189. PubMed ID: 29428602
[TBL] [Abstract][Full Text] [Related]
13. Unexpected thermodynamic signature for the interaction of hydroxymethylated DNA with MeCP2.
Ortega-Alarcon D; Claveria-Gimeno R; Vega S; Jorge-Torres OC; Esteller M; Abian O; Velazquez-Campoy A
Int J Biol Macromol; 2023 Mar; 232():123373. PubMed ID: 36702223
[TBL] [Abstract][Full Text] [Related]
14. MeCP2 Binding Cooperativity Inhibits DNA Modification-Specific Recognition.
Khrapunov S; Tao Y; Cheng H; Padlan C; Harris R; Galanopoulou AS; Greally JM; Girvin ME; Brenowitz M
Biochemistry; 2016 Aug; 55(31):4275-85. PubMed ID: 27420643
[TBL] [Abstract][Full Text] [Related]
15. Rett syndrome-causing mutations in human MeCP2 result in diverse structural changes that impact folding and DNA interactions.
Ghosh RP; Horowitz-Scherer RA; Nikitina T; Gierasch LM; Woodcock CL
J Biol Chem; 2008 Jul; 283(29):20523-34. PubMed ID: 18499664
[TBL] [Abstract][Full Text] [Related]
16. Structural analyses reveal that MBD3 is a methylated CG binder.
Liu K; Lei M; Wu Z; Gan B; Cheng H; Li Y; Min J
FEBS J; 2019 Aug; 286(16):3240-3254. PubMed ID: 30980593
[TBL] [Abstract][Full Text] [Related]
17. Reading the unique DNA methylation landscape of the brain: Non-CpG methylation, hydroxymethylation, and MeCP2.
Kinde B; Gabel HW; Gilbert CS; Griffith EC; Greenberg ME
Proc Natl Acad Sci U S A; 2015 Jun; 112(22):6800-6. PubMed ID: 25739960
[TBL] [Abstract][Full Text] [Related]
18. Neuronal non-CG methylation is an essential target for MeCP2 function.
Tillotson R; Cholewa-Waclaw J; Chhatbar K; Connelly JC; Kirschner SA; Webb S; Koerner MV; Selfridge J; Kelly DA; De Sousa D; Brown K; Lyst MJ; Kriaucionis S; Bird A
Mol Cell; 2021 Mar; 81(6):1260-1275.e12. PubMed ID: 33561390
[TBL] [Abstract][Full Text] [Related]
19. Structure-specific binding of MeCP2 to four-way junction DNA through its methyl CpG-binding domain.
Galvão TC; Thomas JO
Nucleic Acids Res; 2005; 33(20):6603-9. PubMed ID: 16314321
[TBL] [Abstract][Full Text] [Related]
20. From Function to Phenotype: Impaired DNA Binding and Clustering Correlates with Clinical Severity in Males with Missense Mutations in MECP2.
Sheikh TI; Ausió J; Faghfoury H; Silver J; Lane JB; Eubanks JH; MacLeod P; Percy AK; Vincent JB
Sci Rep; 2016 Dec; 6():38590. PubMed ID: 27929079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
